Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis.

Mod Rheumatol. 2009;19(4):379-83 Authors: Nanke Y, Kawamoto M, Yago T, Chiba J, Yamanaka H, Kotake S Fluvastatin (Fluv) is reported to induce apoptosis in rheumatoid arthritis (RA) synoviocytes through the blocking of protein geranylgeranylation. We report here our investigation of whether geranylgeranylacetone (GGA) induces cell death in RA synoviocytes. Synovial tissues were obtained from patients…

Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?

Rheumatology (Oxford). 2009 Oct;48(10):1185-9 Authors: Bouffi C, Djouad F, Mathieu M, Noël D, Jorgensen C Multipotent mesenchymal stromal cells (MSCs) have raised interest mainly because of cartilage/bone differentiation potential which is now partly eclipsed by their capacity to counteract inflammation and suppress host immune responses as well as to prevent fibrosis. MSCs have been identified…

Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases.

Nat Rev Rheumatol. 2009 Jul;5(7):392-9 Authors: Djouad F, Bouffi C, Ghannam S, Noël D, Jorgensen C Mesenchymal stem cells (MSCs), or multipotent mesenchymal stromal cells as they are also known, have been identified in bone marrow as well as in other tissues of the joint, including adipose, synovium, periosteum, perichondrium, and cartilage. These cells are…

Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.

Mod Rheumatol. 2009;19(5):522-9 Authors: Terabe F, Kitano M, Kawai M, Kuwahara Y, Hirano T, Arimitsu J, Hagihara K, Shima Y, Narazaki M, Tanaka T, Kawase I, Sano H, Ogata A Overgrowth of the synovium plays an important role in the pathogenesis of rheumatoid arthritis (RA). Platelet-derived growth factor (PDGF) is one of the most potent…

Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.

Arthritis Rheum. 2009 Aug;60(8):2284-93 Authors: Muhammad K, Roll P, Einsele H, Dörner T, Tony HP OBJECTIVE: Transient B cell depletion by rituximab has been used with clinical efficacy in the treatment of patients with rheumatoid arthritis (RA). Previous studies of B cell repopulation have shown long-term numerical reduction in memory B cells. Non-class-switched IgD+CD27+ memory…

Beneficial effects of cellular stress response in traditional spa treatment of rheumatoid arthritis.

Clin Lab. 2009;55(5-6):235-41 Authors: Marković M, Majkić-Singh N, Ignjatović S Patients with rheumatoid arthritis often conduct bathing in hot mineral water with a high concentrations of sulfate compounds in the water and ambient air. We investigated the effect of hyperthermia and sulfur as possible stress factors at transcriptional level in several proinflammatory genes in fibroblast…

Inhibitory effect of triptolide on interleukin-18 and its receptor in rheumatoid arthritis synovial fibroblasts

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009 Jul;25(7):606-8, 611 Authors: Mao XD, Sun SJ, Pei ZY, Zhang LH AIM: To determine the effects of triptolide (TP) on the expression of interleukin-18 (IL-18) and its receptor in phorbol 12-myristate 13-acetate (PMA)-stimulated rheumatoid arthritis synovial fibroblasts (RASF). METHODS: RASF were pretreated with TP…

Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.

Arthritis Res Ther. 2009;11(5):R138 Authors: Thwin MM, Douni E, Arjunan P, Kollias G, Kumar PV, Gopalakrishnakone P INTRODUCTION: Secretory phospholipase A2 (sPLA2) and matrix metalloproteinase (MMP) inhibitors are potent modulators of inflammation with therapeutic potential, but have limited efficacy in rheumatoid arthritis (RA). The objective of this study was to understand the inhibitory mechanism of…

New advances in the management of juvenile idiopathic arthritis–1: non-biological therapy.

Arch Dis Child Educ Pract Ed. 2009 Oct;94(5):144-50 Authors: Beresford MW, Baildam EM Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA. Key to this has been the serious collaborative…

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

Haematologica. 2010 Feb;95(2):284-92 Authors: Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kötter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R BACKGROUND: Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies.…